Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
17.14B | 14.91B | 17.43B | 17.23B | 14.63B | 10.04B | Gross Profit |
8.24B | 7.05B | 7.78B | 7.87B | 6.81B | 4.61B | EBIT |
5.30B | 4.26B | 5.17B | 5.38B | 4.48B | 2.67B | EBITDA |
5.83B | 4.91B | 5.64B | 5.72B | 4.79B | 2.94B | Net Income Common Stockholders |
4.66B | 3.83B | 4.51B | 4.61B | 3.91B | 2.25B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
5.67B | 5.85B | 5.37B | 3.66B | 5.73B | 6.71B | Total Assets |
18.28B | 18.74B | 18.78B | 17.20B | 15.89B | 14.56B | Total Debt |
4.98B | 4.98B | 5.01B | 5.01B | 5.00B | 5.81B | Net Debt |
-688.78M | -864.52M | -325.51M | 1.48B | 583.42M | 895.55M | Total Liabilities |
10.26B | 10.21B | 10.57B | 10.92B | 9.86B | 9.38B | Stockholders Equity |
8.02B | 8.54B | 8.21B | 6.28B | 6.03B | 5.18B |
Cash Flow | Free Cash Flow | ||||
4.09B | 4.26B | 4.68B | 2.55B | 3.24B | 1.92B | Operating Cash Flow |
4.48B | 4.65B | 5.18B | 3.10B | 3.59B | 2.13B | Investing Cash Flow |
-680.45M | -370.61M | -534.56M | 612.27M | 73.27M | -244.08M | Financing Cash Flow |
-4.00B | -4.00B | -2.83B | -4.58B | -4.17B | -623.93M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | $134.82B | 20.20 | 36.37% | 0.96% | 6.12% | -5.66% | |
81 Outperform | $184.05B | 82.14 | 3.90% | ― | 21.71% | 99.00% | |
78 Outperform | $107.22B | 23.35 | 53.14% | 1.05% | 20.33% | 31.89% | |
78 Outperform | $290.12B | 31.55 | 55.21% | 0.79% | 16.46% | 21.29% | |
74 Outperform | $104.51B | 28.72 | 104.10% | 0.80% | 20.44% | 44.14% | |
60 Neutral | $11.56B | 10.24 | -7.04% | 2.94% | 7.46% | -10.54% | |
45 Neutral | $92.78B | ― | -18.66% | 2.35% | -3.97% | -562.40% |
On May 20, 2025, Lam Research Corporation’s Board of Directors amended the company’s bylaws to allow stockholders owning at least 20% of the company’s shares for over a year to call special meetings. This change aims to ensure stockholders receive timely and accurate information while preventing resource wastage from redundant meetings.
The most recent analyst rating on (LRCX) stock is a Buy with a $102.50 price target. To see the full list of analyst forecasts on Lam Research stock, see the LRCX Stock Forecast page.